Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bempedoic Acid/Ezetimibe/Rosuvastatin FDC in Healthy Participants
NCT07201545Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bempedoic acid, ezetimibe and rosuvastatin in hypercholesterolemia, sponsored by Daiichi Sankyo Co., Ltd. Started Oct 2025; status: completed.
02
Drugs
bempedoic acidezetimiberosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07201545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07201545.